These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27667332)

  • 1. A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly.
    Levin Y; Kochba E; Shukarev G; Rusch S; Herrera-Taracena G; van Damme P
    Vaccine; 2016 Oct; 34(44):5262-5272. PubMed ID: 27667332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: evaluation of immunogenicity, cross-protection, safety and tolerability.
    Ansaldi F; Orsi A; de Florentiis D; Parodi V; Rappazzo E; Coppelli M; Durando P; Icardi G
    Hum Vaccin Immunother; 2013 Mar; 9(3):591-8. PubMed ID: 23295262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V; Klap JM; Seiberling MK; Herzog C; Hartmann K; Kürsteiner O; Kompier R; Grimaldi R; Goudsmit J
    Vaccine; 2009 Jun; 27(27):3561-7. PubMed ID: 19464535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
    Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli C; Groth N; Levin Y; Del Giudice G
    Hum Vaccin Immunother; 2014; 10(6):1701-10. PubMed ID: 24732325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months.
    Esposito S; Marchisio P; Ansaldi F; Bianchini S; Pacei M; Baggi E; Trabattoni D; Icardi G; Principi N
    Vaccine; 2010 Aug; 28(38):6137-44. PubMed ID: 20670909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.
    Hung IF; Levin Y; To KK; Chan KH; Zhang AJ; Li P; Li C; Xu T; Wong TY; Yuen KY
    Vaccine; 2012 Oct; 30(45):6427-35. PubMed ID: 22910287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
    Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
    Frenck RW; Belshe R; Brady RC; Winokur PL; Campbell JD; Treanor J; Hay CM; Dekker CL; Walter EB; Cate TR; Edwards KM; Hill H; Wolff M; Leduc T; Tornieporth N
    Vaccine; 2011 Aug; 29(34):5666-74. PubMed ID: 21699951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.
    Nicholson KG; Thompson CI; Klap JM; Wood JM; Batham S; Newman RW; Mischler R; Zambon MC; Stephenson I
    Vaccine; 2009 Dec; 28(1):171-8. PubMed ID: 19799843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.
    Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli G; Groth N; Del Giudice G
    Hum Vaccin Immunother; 2012 Feb; 8(2):216-27. PubMed ID: 22426371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.
    Cox RJ; Pedersen G; Madhun AS; Svindland S; Sævik M; Breakwell L; Hoschler K; Willemsen M; Campitelli L; Nøstbakken JK; Weverling GJ; Klap J; McCullough KC; Zambon M; Kompier R; Sjursen H
    Vaccine; 2011 Oct; 29(45):8049-59. PubMed ID: 21864624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunogenicity and safety of a single 0.5 mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥6 to <36 months: data from a randomized, Phase III study.
    Esposito S; Marchisio P; Montinaro V; Bianchini S; Weverling GJ; Pariani E; Amendola A; Fabiano V; Pivetti V; Zanetti A; Zuccotti GV
    Vaccine; 2012 Nov; 30(49):7005-12. PubMed ID: 23059357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: are all delivery methods the same?
    Levin Y; Kochba E; Kenney R
    Vaccine; 2014 Jul; 32(34):4249-52. PubMed ID: 24930715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.
    Camilloni B; Basileo M; Valente S; Nunzi E; Iorio AM
    Hum Vaccin Immunother; 2015; 11(3):553-63. PubMed ID: 25714138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
    de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
    Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients.
    Esposito S; Meregalli E; Daleno C; Ghio L; Tagliabue C; Valzano A; Serra D; Galeone C; Edefonti A; Principi N
    Nephrol Dial Transplant; 2011 Jun; 26(6):2018-24. PubMed ID: 20974645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
    Esposito S; Tagliaferri L; Daleno C; Valzano A; Picciolli I; Tel F; Prunotto G; Serra D; Galeone C; Plebani A; Principi N
    Vaccine; 2011 Feb; 29(8):1677-82. PubMed ID: 21199699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.